Granted Patent
B2
US 12,497,404 · App. 19/182,977 · Granted Dec 16, 2025
Morphic forms of trilaciclib and methods of manufacture thereof
Inventors:
Stephen Schneider (Raleigh, NC); Alexander Smith (Apex, NC); Hannah S. White (Chapel Hill, NC); Jay Copeland Strum (Hillsborough, NC); Jaroslaw Mazurek (Amsterdam, NL)
Assignee:
Pharmacosmos Holding A/S
View Patent ↗
Loading inventors, assignments & file history…
Abstract
An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a dihydrochloride salt or a dihydrochloride, dihydrate.
Claims (12)
1 . A crystalline compound of structure:
which is a dihydrochloride characterized by an X-ray powder diffraction (XRPD) pattern comprising at least three 2theta values selected from 8.1±0.2°, 14.8±0.2°, 16.5±0.2°, 18.1±0.2°, 19.7±0.2°, 24.8±0.2°, and 27.7±0.2°.
2 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises at least the 2theta value of 8.1±0.2°.
3 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises at least the 2theta value of 16.5±0.2°.
4 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises at least the 2theta value of 24.8±0.2°.
5 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises at least four 2theta values selected from 8.1±0.2°, 14.8±0.2°, 16.5±0.2°, 18.1±0.2°, 19.7±0.2°, 24.8±0.2°, and 27.7±0.2°.
6 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises at least five 2theta values selected from 8.1±0.2°, 14.8±0.2°, 16.5±0.2°, 18.1±0.2°, 19.7±0.2°, 24.8±0.2°, and 27.7±0.2°.
7 . The crystalline compound of claim 6 , wherein the XRPD pattern comprises at least the 2theta value of 8.1±0.2°.
8 . The crystalline compound of claim 6 , wherein the XRPD pattern comprises at least the 2theta value of 16.5±0.2°.
9 . The crystalline compound of claim 6 , wherein the XRPD pattern comprises at least the 2theta value of 24.8±0.2°.
10 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises at least six 2theta values selected from 8.1±0.2°, 14.8±0.2°, 16.5±0.2°, 18.1±0.2°, 19.7±0.2°, 24.8±0.2°, and 27.7±0.2°.
11 . The crystalline compound of claim 1 , wherein the XRPD pattern comprises the 2theta values 8.1±0.2°, 14.8±0.2°, 16.5±0.2°, 18.1±0.2°, 19.7±0.2°, 24.8±0.2°, and 27.7±0.2°.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 23, 2025
From: PHARMACOSMOS THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 071018/0421 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 23, 2025
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 071018/0502 →
Continuity (5)
Continuation
17097854
· Nov 13, 2020
Provisional Application
63039372
· Jun 15, 2020
References Cited (347)
US 5591855A
· Hudkins et al.
· 1997
[cited by applicant]
US 5628984A
· Boucher
· 1997
[cited by applicant]
US 6291504B1
· Nugiel et al.
· 2001
[cited by applicant]
US 6369086B1
· Davis et al.
· 2002
[cited by applicant]
US 6610684B2
· Zaharevitz et al.
· 2003
[cited by applicant]
US 6667346B2
· Reddy et al.
· 2003
[cited by applicant]
US 6936612B2
· Barvian et al.
· 2005
[cited by applicant]
US 6962993B2
· Blumenkopf et al.
· 2005
[cited by applicant]
US 6982277B2
· Gudkov et al.
· 2006
[cited by applicant]
US 7208489B2
· Barvain et al.
· 2007
[cited by applicant]
US 7345171B2
· Beylin et al.
· 2008
[cited by applicant]
US 7482354B2
· Traquandi et al.
· 2009
[cited by applicant]
US 7855211B2
· Coates et al.
· 2010
[cited by applicant]
US 7977347B2
· Qian et al.
· 2011
[cited by applicant]
US 8598186B2
· Tavares et al.
· 2013
[cited by applicant]
US 8598197B2
· Tavares et al.
· 2013
[cited by applicant]
US 8691830B2
· Tavares et al.
· 2014
[cited by applicant]
US 8822683B2
· Tavares et al.
· 2014
[cited by applicant]
US 8829012B2
· Tavares et al.
· 2014
[cited by applicant]
US 9102682B2
· Tavares et al.
· 2015
[cited by applicant]
US 9260442B2
· Tavares
· 2016
[cited by applicant]
US 9464092B2
· Strum et al.
· 2016
[cited by applicant]
US 9481691B2
· Tavares et al.
· 2016
[cited by applicant]
US 9487530B2
· Strum et al.
· 2016
[cited by applicant]
US 9499564B2
· Tavares et al.
· 2016
[cited by applicant]
US 9527857B2
· Strum et al.
· 2016
[cited by applicant]
US 9683048B2
· Freeman et al.
· 2017
[cited by applicant]
US 9717735B2
· Strum et al.
· 2017
[cited by applicant]
US 9745316B2
· Tavares
· 2017
[cited by applicant]
US 9856268B2
· Tavares
· 2018
[cited by applicant]
US 9931345B2
· Strum et al.
· 2018
[cited by applicant]
US 9957276B2
· Tavares et al.
· 2018
[cited by applicant]
US 20020042412A1
· Zaharevitz et al.
· 2002
[cited by applicant]
US 20030224522A1
· de Jong et al.
· 2003
[cited by applicant]
US 20040006074A1
· Kelley et al.
· 2004
[cited by applicant]
US 20040236084A1
· Biwersi et al.
· 2004
[cited by applicant]
US 20050222163A1
· Eck et al.
· 2005
[cited by applicant]
US 20050267073A1
· Dairi et al.
· 2005
[cited by applicant]
US 20070270362A1
· Harlan et al.
· 2007
[cited by applicant]
US 20080161355A1
· Curry et al.
· 2008
[cited by applicant]
US 20080182853A1
· Kruman et al.
· 2008
[cited by applicant]
US 20110224221A1
· Sharpless et al.
· 2011
[cited by applicant]
US 20110224227A1
· Sharpless et al.
· 2011
[cited by applicant]
US 20120100100A1
· Sharpless et al.
· 2012
[cited by applicant]
US 20140271460A1
· Strum et al.
· 2014
[cited by applicant]
US 20140274896A1
· Strum et al.
· 2014
[cited by applicant]
US 20150297606A1
· Strum et al.
· 2015
[cited by applicant]
US 20150297607A1
· Strum et al.
· 2015
[cited by applicant]
US 20150297608A1
· Strum et al.
· 2015
[cited by applicant]
US 20160045509A1
· Strum et al.
· 2016
[cited by applicant]
US 20160185870A1
· Van Eenennaam
· 2016
[cited by applicant]
US 20160220569A1
· Strum et al.
· 2016
[cited by applicant]
US 20160310499A1
· Strum et al.
· 2016
[cited by applicant]
US 20170119774A1
· Strum et al.
· 2017
[cited by applicant]
US 20170209574A1
· Cao et al.
· 2017
[cited by applicant]
US 20170246171A1
· Strum et al.
· 2017
[cited by applicant]
US 20220175787A1
· Roberts et al.
· 2022
[cited by applicant]
US 20220241275A1
· Strum et al.
· 2022
[cited by applicant]
US 20230146638A1
· Sorrentino et al.
· 2023
[cited by applicant]
US 20230248733A1
· Strum et al.
· 2023
[cited by applicant]
US 20230364098A1
· Strum et al.
· 2023
[cited by applicant]
US 20230381189A1
· Strum et al.
· 2023
[cited by applicant]
US 20240109906A1
· Tavares et al.
· 2024
[cited by applicant]
US 20240139196A1
· Beelen et al.
· 2024
[cited by applicant]
US 20250101030A1
· Schneider et al.
· 2025
[cited by applicant]
CA 2656290A1
· 2008
[cited by applicant]
WO WO1998033798A2
· 1998
[cited by applicant]
WO WO1999015500A1
· 1999
[cited by applicant]
WO WO2001012188A1
· 2001
[cited by applicant]
WO WO2002044174A2
· 2002
[cited by applicant]
WO WO2003062236A1
· 2003
[cited by applicant]
WO WO2005005426A1
· 2005
[cited by applicant]
WO WO2005040166A1
· 2005
[cited by applicant]
WO WO2005052147A2
· 2005
[cited by applicant]
WO WO2005094830A1
· 2005
[cited by applicant]
WO WO2005105213A2
· 2005
[cited by applicant]
WO WO2006074985A1
· 2006
[cited by applicant]
WO WO2006127587A1
· 2006
[cited by applicant]
WO WO2007025090A2
· 2007
[cited by applicant]
WO WO2007048847A2
· 2007
[cited by applicant]
WO WO2007065820A1
· 2007
[cited by applicant]
WO WO2007124252A2
· 2007
[cited by applicant]
WO WO2008005538A2
· 2008
[cited by applicant]
WO WO2008079933A2
· 2008
[cited by applicant]
WO WO2009003003A2
· 2008
[cited by applicant]
WO WO2009061345A2
· 2009
[cited by applicant]
WO WO2009085185A1
· 2009
[cited by applicant]
WO WO2010012777A1
· 2010
[cited by applicant]
WO WO2010020675A1
· 2010
[cited by applicant]
WO WO2010039997A2
· 2010
[cited by applicant]
WO WO2010051127A2
· 2010
[cited by applicant]
WO WO2010132725A2
· 2010
[cited by applicant]
WO WO2011101409A1
· 2011
[cited by applicant]
WO WO2011101417A1
· 2011
[cited by applicant]
WO WO2011103485A1
· 2011
[cited by applicant]
WO WO2012061156A1
· 2012
[cited by applicant]
WO WO2012068381A2
· 2012
[cited by applicant]
WO WO2012129344A1
· 2012
[cited by applicant]
WO WO2013006532A1
· 2013
[cited by applicant]
WO WO2013014448A1
· 2013
[cited by applicant]
WO WO2013148748A1
· 2013
[cited by applicant]
WO WO2013163239A1
· 2013
[cited by applicant]
WO WO2014085318A1
· 2014
[cited by applicant]
WO WO2014144326A1
· 2014
[cited by applicant]
WO WO2014144596A2
· 2014
[cited by applicant]
WO WO2014144740A2
· 2014
[cited by applicant]
WO WO2014144847A2
· 2014
[cited by applicant]
WO WO2014168975A1
· 2014
[cited by applicant]
WO WO2015061407A1
· 2015
[cited by applicant]
WO WO2015084892A1
· 2015
[cited by applicant]
WO WO2015161283A1
· 2015
[cited by applicant]
WO WO2015161285A1
· 2015
[cited by applicant]
WO WO2015161287A1
· 2015
[cited by applicant]
WO WO2015161288A1
· 2015
[cited by applicant]
WO WO2016040848A1
· 2016
[cited by applicant]
WO WO2016040858A1
· 2016
[cited by applicant]
WO WO2016040892A1
· 2016
[cited by applicant]
WO WO2016100561A2
· 2016
[cited by applicant]
WO WO2016126889A1
· 2016
[cited by applicant]
WO WO2017222958A1
· 2017
[cited by applicant]
WO WO2018089518A1
· 2018
[cited by applicant]
WO WO2018091999A1
· 2018
[cited by applicant]
WO WO2018099952A1
· 2018
[cited by applicant]
WO WO2018106729A1
· 2018
[cited by applicant]
WO WO2018156812A1
· 2018
[cited by applicant]
WO WO2018183479A1
· 2018
[cited by applicant]
WO WO2019006393A1
· 2019
[cited by examiner]
WO WO2019108589A1
· 2019
[cited by applicant]
WO WO2020041770A1
· 2020
[cited by applicant]
U.S. Appl. No. 19/182,966, filed Apr. 18, 2025, Morphic forms of trilaciclib and methods of manufa.
[cited by examiner]
U.S. Appl. No. 19/182,985, filed Apr. 18, 2025, Morphic forms of trilaciclib and methods of manufa.
[cited by examiner]
An, H. X. et al., “Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation” American Journal of Pathology, 154: 113-118, 1999.
[cited by applicant]
Anderson, M. S. and Bluestone, J. A., “The NOD mouse: a model of immune dysregulation” Annu Rev Immunol, 23: 447-485, 2005.
[cited by applicant]
Barginear, M. F. and Budman, D. R., “Trastuzumab-DM1: A review of the novel immuno-conjugate for HER2-overexpressing breast cancer” The Open Breast Cancer Journal, 1: 25-30, 2009.
[cited by applicant]
Baughn, L. B. et al., “A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6” Cancer Res., 66(15): 7661-…
[cited by applicant]
Bisi et al., “Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors” Oncotarget., doi: 10.18…
[cited by applicant]
Bisi, J. E. et al., “Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression” Molecular Cancer Therapeutics, 15(5), 783-793, XP055457141, 2016.
[cited by applicant]
Blachly et al., “Emerging Drug Profile: Cyclin-dependent kinase inhibitors” Leuk. Lymphoma, 54(10), 2133-2143, 2013.
[cited by applicant]
Blagosklonny, M. V. and Pardee, A. B., “Exploiting cancer cell cycling for selective protection of normal cells” Cancer Res, 61(11): 4301-4305, Jun. 1, 2001.
[cited by applicant]
Bose et al., “Cyclin-dependent kinase inhibitor therapy for hematologic malignancies” Expert Opin. Investig. Drugs, 22(6), 723-738, 2013.
[cited by applicant]
Boss et al., “Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patient with advanced …
[cited by applicant]
Braun, D. E. and Griesser, U. J., “Stoichiometric and Nonstoichiometric Hydrates of Brucine” Cryst. Growth Des.; 16, 6111-6121, Aug. 26, 2016.
[cited by applicant]
Brookes et al., “INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence” EMBO J., 21(12): 2936-2945, Jun. 17, 2002.
[cited by applicant]
Bucher, N. and Britten, C. D., “G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer” Br J Cancer, 98(3): 523-528, Feb. 12, 2008.
[cited by applicant]
Burdelya et al., “An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models” Science, 320(5873): 226-230, Apr. 11, 2008.
[cited by applicant]
Chari, R. V., “Targeted cancer therapy: conferring specificity to cytotoxic drugs” Accounts of Chemical Research, 41(1): 98-107, 2008.
[cited by applicant]
Chen, X. et al., “Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G1 arrest” J Natl Cancer Inst., 92(24): 1999-2008, Dec. 20, 2000.
[cited by applicant]
Chin et al., “Cooperative effects of INK4a and ras in melanoma susceptibility in vivo” Genes & Development, 11: 2822-2834, 1997.
[cited by applicant]
Choi et al., “Signaling through cyclin D-dependent kinase” Oncogene, 33, 1890-1903, 2014.
[cited by applicant]
Choi et al., “The requirement for cyclin D function in tumor maintenance” Cancer Cell, 22(4), 438-451, 2012.
[cited by applicant]
Chou, A. et al., “Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer” Gut, 0:1-14, doi: 10.1136.gutjnl-2017-315144, Published online Oct. 28, 2017.
[cited by applicant]
Chu et al., “Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-y1](2,3-difluoro-6-methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo…
[cited by applicant]
Curtin et al., “Distinct Sets of Genetic Alterations in Melanoma” N Engl J Med, 353: 2135-2147, 2005.
[cited by applicant]
Daniel et al., “Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab” ESMO 2019 Congress Poster Abstract #1742PD, 2019.
[cited by applicant]
Daniotti et al., “BRAF alterations are associated with complex mutational profiles in malignant melanoma” Oncogene, 23: 5968-5977, 2004.
[cited by applicant]
Davis, S. T. et al., “Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors” Science, 291(5501): 134-137, Jan. 5, 2001.
[cited by applicant]
Davis, S.T. et al., “Retraction” Science, 298(5602): 2327, Dec. 20, 2002.
[cited by applicant]
Davis, T. A. et al., “Genistein induces radioprotection by hematopoietic stem cell quiescence” Int J Radiat Biol, 84(9): 713-726, Sep. 2008.
[cited by applicant]
Decker et al., “Expression of Cyclin E in resting and activated B-chronic lymphocytic leukemia cells: cyclin E/cdk2 as potential therapeutic target” British Journal of Hematology, 125, 141-148, Jan. 13, 2004.
[cited by applicant]
Deep, G. et al., “New Combination Therapies with Cell Cycle Agents” Current Opinion in Investigational Drugs, 9: 591-605, 2008.
[cited by applicant]
Deng et al., “New Strategies in the Treatment of Mantle Cell Lymphoma” Clinical Cancer Research, 18(13): 3499-3508, 2012.
[cited by applicant]
Deng et al., “CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation” Cancer Discovery, doi: 10.1158/2159-8290.CD-17-0915, Published online Nov. 3, 2017.
[cited by applicant]
Dickson, M. A. and Schwartz, G. K., “Development of cell-cycle inhibitors for cancer therapy” Curr Oncol, 16(2): 36-43, Mar. 2009.
[cited by applicant]
Dickson, Mark, et al., “Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients with Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma.” J Clin Oncol., 31(16): 2024-2028, Jun. 1, 2013.
[cited by applicant]
Diehl, J. A. “Cycling to Cancer with Cyclin D1” Cancer Biology and Therapy, 1(3): 226-231, 2002.
[cited by applicant]
Disis, M. L., “Mechanism of Action of Immunotherapy” Seminars in Oncology, vol. 41 (5), Suppl. 5, pp. S3-S13, p. S8, col. 1, paragraph 4, 2014.
[cited by applicant]
El-Diery, W. S., “Meeting report: The international conference on tumor progression and therapeutic resistance” Cancer Res, 65(11): 4475-4484, Jun. 1, 2005.
[cited by applicant]
Engler et al., “Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles” Bioorg Med Chem Lett, 13(14): 2261-2267, Jul. 21, 2003.
[cited by applicant]
EU Clinical Trials Register, pp. 1-5, Feb. 28, 2020.
[cited by applicant]
Finn et al., “PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro” Breast Cancer Research, 11(5): R7…
[cited by applicant]
Finn et al., Abstract S1-6: “Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− adv…
[cited by applicant]
Firer, M. A. and Gellerman, G. J., “Targeted drug delivery for cancer therapy: the other side of antibodies” J. Hematol. Oncol., 5:70, retrieved from http://www.jhoonline.org/content/5/1/70 on Jul. 16, 2014, 2012.
[cited by applicant]
Fry, D. W. et al., “Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts” Mol Cancer Ther., 3(11): 1427-1438, Nov. 2004.
[cited by applicant]
Giacinti et al., “RB and cell cycle progression” Oncogene, 25, 5220-5227, 2006.
[cited by applicant]
Goel, S. et al., “CDK4/6 Inhibition Triggers Anti-Tumour Immunity” Nature, 548 (7668): 471-475. doi: 10.1038/nature23465. Epub Aug. 16, 2017, Aug. 24, 2017.
[cited by applicant]
Gojo et al., “Phase II study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with advanced acute leukemia” Blood, 116(21), 3287, 2010.
[cited by applicant]
Goldberg et al., “Pyrazinoindolone inhibitors of MAPKAP-K2” Bioogranic & Medicinal Chemistry Letters, 18, 938-941, Dec. 23, 2007.
[cited by applicant]
GTHX Corp Presentation, “Next Generation Cancer Therapies” Presented Jan. 2020.
[cited by applicant]
Guillard et al., “Synthesis and biological evaluations of new pyrrolo[2,3-b]pyrimidine as SDI analogs” Heterocycles, vol. 75(5), pp. 1163-1189, 2008.
[cited by applicant]
Guo et al., “Staurosporine modulates radiosensitivity and radiation-induced apoptosis in U937 cells” Int J Radiat Biol., 82(2): 97-109, Feb. 2006.
[cited by applicant]
Hallahan, D. E. et al., “Inhibition of protein kinases sensitizes human tumor cells to ionizing radiation” Radiat Res., 129(3): 345-350, Mar. 1992.
[cited by applicant]
Hamilton et al., “Synergism of Cyclin-Dependent Kinase Inhibitors with Camptothecin Derivatives in Small Cell Lung Cancer Cell Lines” Molecules, 19(2): 2077-2088, 2014.
[cited by applicant]
Hamilton et al., “Synergistic Anticancer Activity of Topotecan—Cyclin-Dependent Kinase Inhibitor Combinations against Drug-Resistant Small Cell Lung Cancer (SCLC) Cell Lines” Journal of Cancer Therapy, 4: 47-53, 2013.
[cited by applicant]
Hara, E. et al., “Regulation of p16
[cited by applicant]
He et al., “Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion” Science Translational Medicine, 9, 13986, 2017.
[cited by applicant]
Herodin, F. et al., “Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma-irradiation promotes survival” Blood, 101(7): 2609-2616, Apr. 1, 2003.
[cited by applicant]
Hershman, D et al., “Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy” J Natl Cancer Inst, 99(3): 196-205, Feb. 7, 200…
[cited by applicant]
Hibbs, M. L. et al., “Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease” Cell, 83(2): 301-311, Oct. 20, 1995.
[cited by applicant]
Hirose, Y. et al., “Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells” Cancer Res, 61(15): 5843-5849, Aug. 1, 2001.
[cited by applicant]
Honma, T. et al., “A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues” J Med Chem, 44(26): 4628-4640, Dec. 20, 2001.
[cited by applicant]
Honma, T. et al., “Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design” J Med Chem, 44(26): 4615-4627, Dec. 20, 2001.
[cited by applicant]
Humphreys, B. D. et al., “Intrinsic epithelial cells repair the kidney after injury” Cell Stem Cell, 2: 284-291, 2008.
[cited by applicant]
Humphreys, B.D. et al., “Repair of injured proximal tubule does not involve specialized progenitors” Proc Natl Acad Sci USA, 108: 9226-9231, 2011.
[cited by applicant]
Ikuta, M. et al., “Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein” J Biol Chem, 276(29): 27548-27554, Jul. 20, 2001.
[cited by applicant]
Johnson et al., “Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor—chemotherapy combinations as an anticancer strategy for solid tumors” Expert Opin Ther Targets, 14(11): 1199-1212…
[cited by applicant]
Johnson, D. G. and Walker, C. L., “Cyclins and Cell Cycle Checkpoints” Annual Review of Pharmacology and Toxicology, 39: 295-312, Apr. 1999.
[cited by applicant]
Johnson, N. and Shapiro, G., “Cyclin-dependent kinase 4/6 inhibition in cancer therapy”, Cell Cycle, 11(21): 3913-3918, Nov. 1, 2012.
[cited by applicant]
Johnson, S. M. et al., “Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition” J Clin Invest, 120(7): 2528-2536, Jul. 2010.
[cited by applicant]
Karaman, M. W. et al., “A quantitative analysis of kinase inhibitor selectivity” Nat Biotechnol., 26(1): 127-132, Jan. 2008.
[cited by applicant]
Khuri, F. R., “Weighing the hazards of erythropoiesis stimulation in patients with cancer” N Engl J Med, 356(24): 2445-2448, Jun. 14, 2007.
[cited by applicant]
Kiang et al., “Structural studies of a non-stoichiometric channel hydrate using high resolution X-ray powder diffraction, solid-state nuclear magnetic resonance, and moisture sorption methods” J. Pharm. Sci., 103:2809-2…
[cited by applicant]
Kiel et al., “SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells” Cell, 121: 1109-1121, 2005.
[cited by applicant]
Knockaert et al., “Pharmacological inhibitors of cyclin-dependent kinases” Trends Pharmacol Sci, 23(9): 417-425, Sep. 2002.
[cited by applicant]
Konecny, Gottfried E. et al., “Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer” Clinical Cancer Research, vol. 17, No. 6, p. 1591-1602, 2011.
[cited by applicant]
Kubinyi, “3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity” Springer, vol. 2-3, (800 pages). p. 243-44, 1998.
[cited by applicant]
Kubo et al., “The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4” Clin Cancer Res, 5: 4279-4286, 1999.
[cited by applicant]
Landis, M. W. et al., “Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis” Cancer Cell, 9: 13-22, 2006.
[cited by applicant]
Laredo, J. et al., “Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells” Blood, 84(1): 229-237, Jul. 1, 1994.
[cited by applicant]
Le Deley et al., “Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer” J Clin Oncol, 25: 292-300, 2007.
[cited by applicant]
Malumbres, M. and Barbacid, M., “Cell cycle, CDKs and cancer: a changing paradigm” Nature Reviews Cancer, 9(3): 153-166, Mar. 2009.
[cited by applicant]
Malumbres, M. and Barbacid, M., “Mammalian cyclin-dependent kinases” Trends Biochem. Sci., 30(11): 630-641, Nov. 2005.
[cited by applicant]
Matsui, K. et al., “Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer” British Journal of Cancer 77(11), pp. 1961-1965, abstract, 1998.
[cited by applicant]
Mcclendon et al., “CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy” Cell Cycle, 11(14), 2747-2755, 2012.
[cited by applicant]
Mcinnes, C., “Progress in the evaluation of CDK inhibitors as anti-tumor agents” Drug Discovery Today, 13, (19/20), 875-881, 2008.
[cited by applicant]
Menu, E. et al., “A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model” Cancer Res, 68(14): 5519-5523, Jul. 15, 2008.
[cited by applicant]
Michaud, Karine et al., “Pharmacologic inhibition of cdk4/6 arrests the growth of glioblastoma multiforme intracranial xenografts” Cancer Res, 70: 3228-3238, Apr. 15, 2011.
[cited by applicant]
Mino, R Caira., “Crystalline Polymorphism of Organic Compounds” Topics in Current Chemistry, Springer, berlin, DE, 198, 163-208; ISSN: 0340-1022; DOI: 10.1007/3-540-69178-2_5, 1998.
[cited by applicant]
Mita et al., “Randomized Phase II trial of the cyclin-dependent kinase inhibitors Dinaciclib (MK-7965) versus Capecitabine in patients with advanced breast cancer” Clinical Breast Cancer, 14(3), 169-176, 2014.
[cited by applicant]
Morgan, D.O., “Cyclin-dependent Kinases: Engines, Clocks, and Microprocessors” Annual Review of Cell and Developmental Biology, 13: 261-291, 1997.
[cited by applicant]
NCT02079636—A Study of Abemaciclib (LY2835219) in Combination with Another Anticancer Drug in Participants with Lung Cancer (NSCLC); Mar. 6, 2014.
[cited by applicant]
NCT02693535—TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People with Advanced Stage Cancer (TAPUR); Feb. 26, 2016.
[cited by applicant]
NCT02779751—A Study of Abemaciclib (LY2835219) in Participants with Non-Small Cell Lung Cancer or Breast Cancer; May 20, 2016.
[cited by applicant]
NCT03041311—Carboplatin, Etoposide, and Atezolizumab with or without Trilaciclib; Jul. 26, 2019.
[cited by applicant]
NCT03294694—Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer; Sep. 27, 2017.
[cited by applicant]
O'Dwyer, et al., “A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991” J Clin Oncol, 25(18S): 3550, Abstract, 2007.
[cited by applicant]
Ojeda, F. et al., “Role of protein kinase-C in thymocyte apoptosis induced by irradiation” Int J Radiat Biol., 61(5): 663-667, May 1992.
[cited by applicant]
Ottensmeier, et. al., “A Novel Phase II Trial of Ipilimumab, Carboplatin and Etoposide (ICE) for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC)” Annals of Oncology 25 (Supplement 4): iv511-iv5…
[cited by applicant]
Parsam et al., “A comprehensive, sensitive and economical approach for the detection of mutations in the RB1 gene in retinoblastoma” Journal of Genetics, 88(4): 517-527, Dec. 2009.
[cited by applicant]
Rader et al., “Dual CDK4/CDK6 inhibition induces cell cycle arrest and senescence in neutroblastoma” Clinical Cancer Res., 19(22), 6173-6182, 2013.
[cited by applicant]
Ramsey, M. R. et al., “Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues” Cancer Res, 67(10): 4732-4741, May 15, 2007.
[cited by applicant]
Reck et al., “Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer” J Clin Oncol., 34:3740-3748, 2016.
[cited by applicant]
Reddy, H. K. et al., “Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis” Cancer Research, 65: 10174-10178, 2005.
[cited by applicant]
Roberts et al., “Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy” JNCI, 104(6):476-487, 2012.
[cited by applicant]
Rocha Lima et al., Abstract “CT151:GIT28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results” Cancer Research…
[cited by applicant]
Ruas et al., “CDK4 and CDK6 Delay Senescence by Kinase-Dependent and p16INK4a-Independent Mechanisms” Molecular and Cellular Biology, 27(12): 4273-4282, Jun. 2007.
[cited by applicant]
Samady, L. et al., “Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor” Cancer Biology & Therapy, 3: 317-323, 2004.
[cited by applicant]
Sanchez-Martinez, C. et al., “Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors” Bioorg Med Chem Lett, 13(21): 3835-3839, Nov. 3, 2003.
[cited by applicant]
Sanchez-Martinez, C. et al., “Studies on cyclin-dependent kinase inhibitors: indolo-[2,3-a]pyrrolo[3,4-c]carbazoles versus bis-indolylmaleimides” Bioorg Med Chem Lett, 13(21): 3841-3846, Nov. 3, 2003.
[cited by applicant]
Sawai, Catherine M., et al., “Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia” Cancer Cell, vol. 22, pp. 452-465, Oct. 16, 2012.
[cited by applicant]
Schmidt, M. and Fan, Z., “Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells” Oncogene, 20(43): 6164-6171, Sep. 27, 2001.
[cited by applicant]
Schwartz, G.K. et al., “Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)” Br J Cancer, 104(12): 1862-1868, Jun. 7, 2011.
[cited by applicant]
Seed, T. M., “Radiation protectants: current status and future prospects” Health Phys, 89(5): 531-545, Nov. 2005.
[cited by applicant]
Sharma, P.S. et al., “Inhibitors of cyclin dependent kinases: useful targets for cancer treatment” Curr. Cancer Drug Targets, 8(1): 53-75, Feb. 2008.
[cited by applicant]
Sharpless et al., “Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo” Oncogene, 22(32): 5055-5059, Aug. 7, 2003.
[cited by applicant]
Sherr, C. J., “Cancer Cell Cycles” Science, 274(5293): 1672-1677, Dec. 6, 1996.
[cited by applicant]
Shields et al., “Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma” Cancer Res, 67: 1502-1512, 2007.
[cited by applicant]
Shimamura, T. et al., “Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9” Bioorg Med Chem Lett., 16(14): 3751-3754, Jul. 15, 2006.
[cited by applicant]
Sielecki et al., “Quinazolines as cyclin dependent kinase inhibitors” Bioogranic & Medicinal Chemistry Letters, 11, 1157-1160, May 7, 2001.
[cited by applicant]
Soni, R. et al., “Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4” J Natl Cancer Inst, 93(6): 436-446, Mar. 21, 2001.
[cited by applicant]
Sorrentino, Jessica et al., Abstract 941: “G1T28-1, a novel CDK 4/6 inhibitor, protects murine hematopoietic stem and progenitor cells from cytotoxic chemotherapy” Cancer Research, 75(15), 941, XP002799586; & 106th Annu…
[cited by applicant]
Sorrentino, Jessica et al., Abstract 5628: “Trilaciclib (G1T28), a CDK 4/6 inhibitor, enhances the efficacy of combination therapy and immune checkpoint inhibitor treatment in preclinical models” Cancer Research, 77(13)…
[cited by applicant]
Stice, James P. et al., “CDK4/6 Therapeutic Intervention and viable alternative to taxane in CRPC” Molecular Cancer Research, 15(6), 660-669, XP55457140, 2017.
[cited by applicant]
Stone, S. et al., “Reversible, p16-mediated cell cycle arrest as protection from chemotherapy” Cancer Research, 56(14): 3199-3202, Jul. 15, 1996.
[cited by applicant]
Tan et al., “Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicenter, randomized, open-label, phase 2 trial” Lancet Oncol., 20, 1587-1601, 2019.
[cited by applicant]
Tao Z et al., “Coadministration of trametinib and palbociclib radiosensitizers KRAS-Mutant non-small cell lung cancers in vitro and in vivo” Cancer Therapy, 22(1), 122-133, 2016.
[cited by applicant]
Teicher, B. A. and Chari, R. V., “Antibody conjugate therapeutics: challenges and potential” Clinical Cancer Research, 17(20): 6389-6397, 2011.
[cited by applicant]
Tong et al., “Phase I and pharmacologic study of SNS-032, a potent and selective CDK2, 7 and 9 inhibitors in patients with advanced chronic lymphocytic leukemia and multiple myeloma” Journal of Clinical Oncology, 28(18)…
[cited by applicant]
Toogood, P. L. et al., “Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6” J Med Chem, 48(7): 2388-2406, Apr. 7, 2005.
[cited by applicant]
Tsou, H. R. et al., “4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4)” J Med Chem, 51(12): 3507-3525, Jun. 26, 2008.
[cited by applicant]
Tsou, H. R. et al., “Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent k…
[cited by applicant]
Tu, S. et al., “New potential inhibitors of cyclin-dependent kinase 4: design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation” Bioorg Med Chem Lett, 16(13): 3578-3581, Jul. 1, 2006.
[cited by applicant]
Uckun, F. M. et al., “In vivo radioprotective effects of recombinant human granulocyte colony-stimulating factor in lethally irradiated mice” Blood, 75(3): 638-645, Feb. 1, 1990.
[cited by applicant]
Vanderwel, S. N. et al., “Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4” J Med Chem., 48(7): 2371-2387, Apr. 7, 2005.
[cited by applicant]
Walker et al., “Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets” Genes Chromosomes & Cancer, 22: 157-163, 1998.
[cited by applicant]
Wang et al., “Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma I atm-deficient mice” Proc Natl Acad Sci, USA, 94: 14590-14595, 1997.
[cited by applicant]
Wang, R. H. et al., “Protein kinase inhibitor staurosporine enhances cytotoxicity of antitumor drugs to cancer cells” Yao Xue Xue Bao, 31(6): 411-415, Abstract, 1996.
[cited by applicant]
Weiss et al., “Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial” Annals of Oncology, 30:1613-1621, 2…
[cited by applicant]
Wermuth, The Practice of Medicinal Chemistry, 2d ed., 768 pages. Chs. 9-10, 2003.
[cited by applicant]
Wilson et al., “Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair” Cell, 135: 1118-1129, 2008.
[cited by applicant]
Yu, Q. et al., “Requirement for CDK4 kinase function in breast cancer” Cancer Cell, 9: 23-32, 2006.
[cited by applicant]
Zhang, et al., “Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3
[cited by applicant]
Zhao, Guisen et al., “Basis for Design and Development of Drugs” Shandong University Press, pp. 93-94, Nov. 30, 2015.
[cited by applicant]
Zhu, G. et al., “Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors” J Med Chem., 46(11): 2027-2030, May 22, 2003.
[cited by applicant]
Zhu, G. et al., “Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors” Bioorg Med Chem Lett, 13(7): 1231-1235, Apr. 7, 2003.
[cited by applicant]
U.S. Appl. No. 18/943,701, Smith et al., Nov. 11, 2024.
[cited by applicant]
U.S. Appl. No. 18/957,373, Tavares et al., Nov. 22, 2024.
[cited by applicant]
U.S. Appl. No. 19/096,395, Schneider et al., Mar. 31, 2025.
[cited by applicant]
U.S. Appl. No. 19/182,966, Schneider et al., Apr. 18, 2025.
[cited by applicant]
U.S. Appl. No. 19/182,985, Schneider et al., Apr. 18, 2025.
[cited by applicant]
U.S. Appl. No. 19/192,045, Strum et al., Apr. 28, 2025.
[cited by applicant]
U.S. Appl. No. 19/232,623, Sorrentino et al., Jun. 9, 2025.
[cited by applicant]
U.S. Appl. No. 19/272,690, Beelen et al., Jul. 17, 2025.
[cited by applicant]
2:25-cv-03218-JXN-AME,
[cited by applicant]
2:25-cv-03945-JXN-AME,
[cited by applicant]
2:25-cv-03967-JXN-AME,
[cited by applicant]
Cruz-Cabeza, Aurora J., Neil Feeder, and Roger J. Davey, “Open questions in organic crystal polymorphism.” Communications Chemistry 3.1: 142, 2020.
[cited by applicant]